{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:17:09Z","timestamp":1767964629390,"version":"3.49.0"},"reference-count":43,"publisher":"Akademiai Kiado Zrt.","issue":"17","license":[{"start":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:00Z","timestamp":1619308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,4,25]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> R\u00e9g\u00f3ta ismert, hogy a daganatokhoz t\u00e1rsul\u00f3\n                    emelkedett v\u00e9rlemezkesz\u00e1m rosszabb t\u00fal\u00e9l\u00e9ssel t\u00e1rsul. Fej-nyak tumoros betegek\n                    eset\u00e9ben kev\u00e9s inform\u00e1ci\u00f3 \u00e1ll rendelkez\u00e9s\u00fcnkre ezzel az \u00f6sszef\u00fcgg\u00e9ssel\n                    kapcsolatban. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Vizsg\u00e1latunk c\u00e9lja a fej-nyak\n                    daganatos betegek progn\u00f3zisa \u00e9s a thrombocytosis k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9s\n                    tanulm\u00e1nyoz\u00e1sa volt. <jats:italic>M\u00f3dszer:<\/jats:italic> K\u00fcl\u00f6nf\u00e9le st\u00e1dium\u00fa \u00e9s\n                    lokaliz\u00e1ci\u00f3j\u00fa, 312, fej-nyak tumoros beteg retrospekt\u00edv adatait elemezt\u00fck. A\n                    m\u0171t\u00e9t el\u0151tti v\u00e9rlemezkesz\u00e1mokat vizsg\u00e1ltuk, a 300 G\/l feletti \u00e9rt\u00e9ket\n                    tekintett\u00fck emelkedett thrombocytasz\u00e1mnak. A v\u00e9rlemezkesz\u00e1m \u00e9s a t\u00fal\u00e9l\u00e9s k\u00f6z\u00f6tti\n                    kapcsolatot Kaplan\u2013Meier-m\u00f3dszerrel \u00e9s multivari\u00e1ns Cox-regresszi\u00f3val elemezt\u00fck.\n                        <jats:italic>Eredm\u00e9nyek:<\/jats:italic> Emelkedett thrombocytasz\u00e1m mellett\n                    szignifik\u00e1nsan rosszabb t\u00fal\u00e9l\u00e9st \u00e9szlelt\u00fcnk (5 \u00e9ves t\u00fal\u00e9l\u00e9s: p = 0,007,\n                    betegs\u00e9gmentes t\u00fal\u00e9l\u00e9s: p = 0,192). Ez az \u00f6sszef\u00fcgg\u00e9s m\u00e9g akkor is fenn\u00e1llt,\n                    amikor multivari\u00e1ns anal\u00edzissel nemre, korra, st\u00e1diumra, differenci\u00e1lts\u00e1gi\n                    fokra, lokaliz\u00e1ci\u00f3ra, valamint feh\u00e9r- \u00e9s v\u00f6r\u00f6sv\u00e9rsejtsz\u00e1mra korrig\u00e1ltuk az\n                    elemz\u00e9st (5 \u00e9ves t\u00fal\u00e9l\u00e9s: p = 0,027). A k\u00fcl\u00f6nf\u00e9le anat\u00f3miai lokaliz\u00e1ci\u00f3kban\n                    elt\u00e9r\u0151 m\u00e9rt\u00e9kben \u00e9szlelt\u00fcnk 300 G\/l feletti v\u00e9rlemezkesz\u00e1mot (algarat: 43,6%,\n                    sub- \u00e9s supraglottis: 35,8%, sz\u00e1j\u00fcreg: 35,7%, hangszalag: 22,5%, sz\u00e1jgarat: 19%,\n                    multiplex: 50%), ez azonban nem befoly\u00e1solta szignifik\u00e1nsan a t\u00fal\u00e9l\u00e9st (p =\n                    0,603). <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A daganathoz t\u00e1rsul\u00f3 thrombocytosis\n                    \u00f6sszef\u00fcgg\u00e9sbe hozhat\u00f3 a fej-nyak tumoros betegek rosszabb t\u00fal\u00e9l\u00e9s\u00e9vel. Az egyes\n                    lokaliz\u00e1ci\u00f3kban tal\u00e1lt k\u00fcl\u00f6nb\u00f6z\u0151 v\u00e9rlemezkesz\u00e1mok nem befoly\u00e1solj\u00e1k elt\u00e9r\u0151\n                    m\u00e9rt\u00e9kben a t\u00fal\u00e9l\u00e9st. Orv Hetil. 2021; 162(17): 676\u2013682.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> The association between cancer-related\n                    thrombocytosis and worse survival has been described with a variety of solid\n                    neoplasms. However, only limited data are available on the prognostic\n                    significance of elevated platelet count in head and neck tumours.\n                        <jats:italic>Objective:<\/jats:italic> We aimed to investigate the correlation between\n                    the survival of patients with head and neck cancer and thrombocytosis.\n                        <jats:italic>Method:<\/jats:italic> We conducted an analysis of the data from 312\n                    patients with head and neck squamous cell carcinoma of various stages and\n                    locations. Preoperative platelet counts were analysed; elevated platelet count\n                    was defined as 300 G\/l or higher. The influence of platelet count on survival\n                    was calculated with the Kaplan\u2013Meier method as well as with multivariate Cox\n                    regression. <jats:italic>Results:<\/jats:italic> In patients with excessive thrombocytosis,\n                    survival was significantly worse (overall survival: p = 0.007, disease-free\n                    survival: p = 0.192). This association remained significant even after adjusting\n                    the multivariate analysis for age, gender as well as tumour stage, grade,\n                    location, red and white blood cell count (overall survival: p = 0.027). The\n                    magnitude of thrombocytosis differed among tumours of different anatomical\n                    locations (hypopharynx: 43.6%, sub- and supraglottis: 35.8%, oral cavity: 35.7%,\n                    vocal cord: 22.5%, oropharynx: 19%, multiple: 50%), but this did not affect\n                    survival significantly (p = 0.603). <jats:italic>Conclusion:<\/jats:italic> Elevated\n                    platelet count may be related to a worse prognosis in head and neck squamous\n                    cell carcinoma patients. The impact of thrombocytosis does not vary with the\n                    anatomical location of the tumour. Orv Hetil. 2021; 162(17): 676\u2013682.<\/jats:p>","DOI":"10.1556\/650.2021.32078","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:05:43Z","timestamp":1630404343000},"page":"676-682","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["A magasabb v\u00e9rlemezkesz\u00e1m mint a fej-nyak tumoros betegek t\u00fal\u00e9l\u00e9ssel kapcsolatos esetleges prognosztikai faktora"],"prefix":"10.1556","volume":"162","author":[{"given":"Zsuzsanna","family":"Szilasi","sequence":"first","affiliation":[{"name":"1 Magyar Honv\u00e9ds\u00e9g Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont, F\u00fcl-Orr-G\u00e9g\u00e9szeti \u00e9s Fej-Nyakseb\u00e9szeti Oszt\u00e1ly, Budapest, R\u00f3bert K\u00e1roly krt. 44., 1134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ria","family":"J\u00f3sa","sequence":"additional","affiliation":[{"name":"2 Jahn Ferenc D\u00e9l-pesti K\u00f3rh\u00e1z, F\u00fcl-Orr-G\u00e9g\u00e9szeti \u00e9s Fej-Nyakseb\u00e9szeti Oszt\u00e1ly, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsombor","family":"Zrubka","sequence":"additional","affiliation":[{"name":"3 Budapesti Corvinus Egyetem, Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zgazdas\u00e1gtan Tansz\u00e9k, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcnde","family":"Mezei","sequence":"additional","affiliation":[{"name":"4 Jahn Ferenc D\u00e9l-pesti K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kereszt\u00e9ly","family":"Merkel","sequence":"additional","affiliation":[{"name":"5 Szent Imre K\u00f3rh\u00e1z, Seb\u00e9szeti Oszt\u00e1ly, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frigyes","family":"Helfferich","sequence":"additional","affiliation":[{"name":"1 Magyar Honv\u00e9ds\u00e9g Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont, F\u00fcl-Orr-G\u00e9g\u00e9szeti \u00e9s Fej-Nyakseb\u00e9szeti Oszt\u00e1ly, Budapest, R\u00f3bert K\u00e1roly krt. 44., 1134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Baranyai","sequence":"additional","affiliation":[{"name":"6 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orostudom\u00e1nyi Kar, I. Seb\u00e9szeti Klinika, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424. [Erratum: CA Cancer J Clin. 2020; 70: 313.]","DOI":"10.3322\/caac.21492"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2 Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.","DOI":"10.1002\/ijc.29210"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3923\/ijp.2018.528.533","article-title":"Effects of regional and general anesthesia on survival in head and neck cancer","volume":"14","author":"3 Wang","year":"2018","unstructured":"3 Wang L, YeErDaoLaiTi Y, Yang G, et al. Effects of regional and general anesthesia on survival in head and neck cancer. Int J Pharmacol. 2018; 14: 528-533.","journal-title":"Int J Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 He Y, Xia T, Bian H, et al. Pretreatment thrombocytosis predicts survival in colorectal cancer. Clin Res Hepatol Gastroenterol. 2016; 40: e59-e60.","DOI":"10.1016\/j.clinre.2016.04.002"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/09537104.2016.1170112","article-title":"Paraneoplastic thrombocytosis in gastrointestinal cancer","volume":"27","author":"Baranyai Zs","year":"2016","unstructured":"5 Baranyai Zs, J\u00f3sa V, T\u00f3th A, et al. Paraneoplastic thrombocytosis in gastrointestinal cancer. Platelets 2016; 27: 269-275.","journal-title":"Platelets"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2015.03.005","article-title":"Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer","volume":"18","author":"6 Josa","year":"2015","unstructured":"6 Josa V, Krzystanek M, Eklund AC, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015; 18: 1-6.","journal-title":"Int J Surg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s12253-015-9925-8","article-title":"Thrombocytosis of liver metastasis from colorectal cancer as predictive factor","volume":"21","author":"7 J\u00f3sa","year":"2015","unstructured":"7 J\u00f3sa V, Krzystanek M, Vass T, et al. Thrombocytosis of liver metastasis from colorectal cancer as predictive factor. Pathol Oncol Res. 2015; 21: 991-997.","journal-title":"Pathol Oncol Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3892\/etm.2014.1699","article-title":"Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer","volume":"8","author":"8 Hu","year":"2014","unstructured":"8 Hu C, Chen R, Chen W, et al. Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med. 2014; 8: 125-132.","journal-title":"Exp Ther Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.7314\/APJCP.2014.15.16.6511","article-title":"Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer","volume":"15","author":"FX","year":"2014","unstructured":"9 Li FX, Wei LJ, Zhang H, et al. Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev. 2014; 15: 6511-6517.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"24327","DOI":"10.18632\/oncotarget.15358","article-title":"The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis","volume":"8","author":"10 Cheng","year":"2017","unstructured":"10 Cheng J, Zeng Z, Ye Q, et al. The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis. Oncotarget 2017; 8: 24327-24336.","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12885-016-2660-z","article-title":"Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records","volume":"16","author":"11 Cozzi","year":"2016","unstructured":"11 Cozzi GD, Samuel JM, Fromal JT, et al. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer 2016; 16: 612.","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12885-016-2070-2","article-title":"Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients","volume":"16","author":"12 Feng","year":"2016","unstructured":"12 Feng Z, Wen H, Bi R, et al. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer 2016; 16: 43.","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ygyno.2015.01.101","article-title":"Preoperative thrombocytosis and leukocytosis among ovarian cancer patients are associated with postoperative death","volume":"137","author":"13 Barber","year":"2015","unstructured":"13 Barber EL, Boggess JF, Van Le L, et al. Preoperative thrombocytosis and leukocytosis among ovarian cancer patients are associated with postoperative death. Gynecol Oncol. 2015; 137: 43.","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3109\/0284186X.2014.1000466","article-title":"Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer","volume":"54","author":"14 Chadha","year":"2015","unstructured":"14 Chadha AS, Kocak-Uzel E, Das P, et al. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015; 54: 971-978.","journal-title":"Acta Oncol"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 Kocak E, Das P, Delclos M, et al. Paraneoplastic thrombocytosis is a significant independent prognostic factor for overall and progression free survival in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014; 90: S365.","DOI":"10.1016\/j.ijrobp.2014.05.1182"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7819-12-37","article-title":"Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer","volume":"12","author":"16 Kim","year":"2014","unstructured":"16 Kim M, Chang H, Yang HC, et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol. 2014; 12: 37.","journal-title":"World J Surg Oncol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Wang J, Luo M, Wu H, et al. Preoperative thrombocytosis as a predictor of unfavorable survival in resectable non-small cell lung cancer. J Clin Oncol. 2013; 31(15 Suppl): e18531.","DOI":"10.1200\/jco.2013.31.15_suppl.e18531"},{"key":"ref17","unstructured":"18 Mar\u00e1z A, Fur\u00e1k J, Varga Z, et al. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res. 2013; 33: 1725-1729."},{"key":"ref18","unstructured":"19 Rajkumar A, Szallasi A. Paraneoplastic thrombocytosis in breast cancer. Anticancer Res. 2013; 33: 4545-4546."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.oraloncology.2006.03.010","article-title":"Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma","volume":"43","author":"CC","year":"2007","unstructured":"20 Lu CC, Chang KW, Chou FC, et al. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007; 43: 283-288.","journal-title":"Oral Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/hed.25366","article-title":"Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: meta-analysis","volume":"40","author":"21 Takenaka","year":"2018","unstructured":"21 Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: meta-analysis. Head Neck 2018; 40: 2714-2723.","journal-title":"Head Neck"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch PM","year":"1994","unstructured":"22 Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.","journal-title":"Biometrika"},{"key":"ref22","unstructured":"23 StataCorp. Statistical Software: Release 14. StataCorp LP, College Station, TX, 2015."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/ijc.27441","article-title":"Tumor-platelet interaction in solid tumors","volume":"130","author":"24 Buergy","year":"2012","unstructured":"24 Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747-2760.","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007; 33: 712-721.","DOI":"10.1055\/s-2007-991540"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"26 Gay","year":"2011","unstructured":"26 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-134.","journal-title":"Nat Rev Cancer"},{"key":"ref26","unstructured":"27 Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59: 1295-1300."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells","volume":"105","author":"28 Palumbo","year":"2005","unstructured":"28 Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000323936","article-title":"Modulation of natural killer cell anti-tumor reactivity by platelets","volume":"3","author":"29 Placke","year":"2011","unstructured":"29 Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011; 3: 374-382.","journal-title":"J Innate Immun"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1182\/blood-2009-10-247296","article-title":"Deadly allies: the fatal interplay between platelets and metastasizing cancer cells","volume":"115","author":"30 Erpenbeck","year":"2010","unstructured":"30 Erpenbeck L, Sch\u00f6n MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-3436.","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"31 Stone","year":"2012","unstructured":"31 Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366: 610-618.","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"32 Ludwig","year":"2004","unstructured":"32 Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33 Birgeg\u00e5rd G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68(Suppl 1): 3-11.","DOI":"10.1159\/000083128"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00432-009-0625-1","article-title":"Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer","volume":"135","author":"34 Chen","year":"2009","unstructured":"34 Chen MH, Chang PM, Chen PM, et al. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol. 2009; 135: 1783-1790.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13277-012-0508-y","article-title":"Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma","volume":"34","author":"35 Gao","year":"2013","unstructured":"35 Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013; 34: 39-45.","journal-title":"Tumour Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-014-0065-5","article-title":"Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma","volume":"7","author":"36 Rachidi","year":"2014","unstructured":"36 Rachidi S, Wallace K, Day TA, et al. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014; 7: 65.","journal-title":"J Hematol Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ijc.29870","article-title":"Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation","volume":"138","author":"37 Shoultz-Henley","year":"2016","unstructured":"37 Shoultz-Henley S, Garden AS, Mohamed AS, et al. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer 2016; 138: 1290-1297.","journal-title":"Int J Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.anl.2016.06.009","article-title":"The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma","volume":"44","author":"38 Pardo","year":"2017","unstructured":"38 Pardo L, Valero C, L\u00f3pez M, et al. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma. Auris Nasus Larynx 2017; 44: 313-318.","journal-title":"Auris Nasus Larynx"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3892\/ol.2015.2872","article-title":"Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients","volume":"9","author":"39 Chen","year":"2015","unstructured":"39 Chen YP, Chen C, Mai ZY, et al. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 2015; 9: 1458-1466.","journal-title":"Oncol Lett"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1055-9965.EPI-18-0408","article-title":"Sex differences in using systemic inflammatory markers to prognosticate patients with head and neck squamous cell carcinoma","volume":"27","author":"40 Lin","year":"2018","unstructured":"40 Lin CY, Kwon H, Rangel Rivera GO, et al. Sex differences in using systemic inflammatory markers to prognosticate patients with head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2018; 27: 1176-1185.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"164906","DOI":"10.4061\/2010\/164906","article-title":"Gender dependence for a subset of the low-abundance signaling proteome in human platelets","volume":"2010","author":"41 Eidelman","year":"2010","unstructured":"41 Eidelman O, Jozwik C, Huang W, et al. Gender dependence for a subset of the low-abundance signaling proteome in human platelets. Hum Genomics Proteomics 2010; 2010: 164906.","journal-title":"Hum Genomics Proteomics"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10555-012-9375-7","article-title":"TGF-\u03b2 signalling and its role in cancer progression and metastasis","volume":"31","author":"Drabsch Y","year":"2012","unstructured":"42 Drabsch Y, ten Dijke P. TGF-\u03b2 signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012; 31: 553-568.","journal-title":"Cancer Metastasis Rev"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3","volume":"198","author":"43 Chen","year":"2003","unstructured":"43 Chen WJ, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3. J Exp Med. 2003; 198: 1875-1886.","journal-title":"J Exp Med"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/17\/article-p676.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/17\/article-p676.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:14:05Z","timestamp":1698758045000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/17\/article-p676.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,25]]},"references-count":43,"journal-issue":{"issue":"17"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32078","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,25]]}}}